Impact of the COVID-19 pandemic on the frequency, clinical spectrum and outcomes of pediatric guillain-Barré syndrome in India: A multicentric ambispective cohort study

Divyani Garg,Rajinder K. Dhamija,Aditya Choudhary,Ritu Shree,Sujit Kumar,Priyanka Samal,Abhishek Pathak,Pamidimukkala Vijaya,Yareeda Sireesha,Sruthi S. Nair,Sanjay Sharma,Soaham Desai,Human P. Sinha,Ayush Agarwal,Ashish Upadhyay,MV Padma Srivastava,Rohit Bhatia,Awadh K. Pandit,Rajesh K. Singh,Alisha Reyaz,PM Yogeesh,Manish Salunkhe,Vivek Lal,Manish Modi,Gagandeep Singh,Monika Singla,Samhita Panda,Maya Gopalakrishnan,Inder Puri,Sudhir Sharma,Bismay Kumar,Prashant K. Kushwaha,Harshadkumar Chovatiya,Teresa Ferreira,Sanjeev K. Bhoi,Manish Bhartiya,Subhash Kaul,Anuja Patil,Neeharika L. Mathukumalli,Madhu Nagappa,P Praveen Sharma,Aneesh Basheer,Dileep Ramachandran,Neetha Balaram,Jospeh Sebastian,Venugopalan Y. Vishnu,VenugopalanY Vishnu,RajinderK Dhamija,SruthiS Nair,HumanP Sinha,AwadhK Pandit,RajeshK Singh,PrashantK Kushwaha,SanjeevK Bhoi,NeeharikaL Mathukumalli,PPraveen Sharma
DOI: https://doi.org/10.4103/aian.aian_392_21
2022-01-01
Annals of Indian Academy of Neurology
Abstract:Objective: To study impact of COVID-19 pandemic on frequency, clinical/electrophysiological profile and treatment outcomes in pediatric Guillain-Barré syndrome (GBS).Background: GBS is the most frequent cause of pediatric acute flaccid paralysis. The effect of the COVID-19 pandemic on pediatric GBS is unclear in the literature.Methods: We conducted an ambispective, multicentric, cohort study involving 12 of 27 centres in GBS Consortium, during two periods: pre-COVID-19 (March-August 2019) and during COVID-19 (March-August 2020). Children ≤12 years who satisfied National Institute of Neurological Diseases and Stroke criteria for GBS/variants were enrolled. Details pertaining to clinical/laboratory parameters, treatment and outcomes (modified Rankin Scale (mRS) at discharge, GBS Disability score at discharge and 3 months) were analysed.Results: We enrolled 33 children in 2019 and 10 in 2020. Children in 2020 were older (median 10.4 [interquartile range 6.75-11.25] years versus 5 (2.5-8.4) years; P = 0.022) and had more sensory symptoms (50% versus 18.2%; P = 0.043). The 2020 group had relatively favourable mRS at discharge (median 1 (1-3.5) versus 3 (2-4); P = 0.042) and GBS disability score at 3 months (median 0 (0-0.75) versus 2 (0-3); P = 0.009) compared to 2019. Multivariate analysis revealed bowel involvement (P = 0.000) and ventilatory support (P = 0.001) as independent predictors of disability. No child in 2020 had preceding/concurrent SARS-CoV2 infection.Conclusions: The COVID-19 pandemic led to a marked decline in pediatric GBS presenting to hospitals. Antecedent illnesses, clinical and electrophysiological profile of GBS remained largely unchanged from the pre-pandemic era.
clinical neurology
What problem does this paper attempt to address?